Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|December 2, 2004
- Pharmaceutical Technology-12-02-2004
- Volume 28
- Issue 11
Robust CRO Market Is Driving New Merger and Acquisition Activity
Author(s)Jim Miller
The blockage in the new product pipeline may be breaking. CROs report increased demand for late-stage development services in their latest round of earnings reports.
Advertisement
Articles in this issue
almost 22 years ago
In the Spotlight-December 2004almost 22 years ago
Safety Problems Roil Pharma and FDAalmost 22 years ago
December 2004almost 22 years ago
The Seventh Annual International Employment Surveyalmost 22 years ago
Pharmaco-FakeryAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement